NO20025277D0 - Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelse - Google Patents
Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelseInfo
- Publication number
- NO20025277D0 NO20025277D0 NO20025277A NO20025277A NO20025277D0 NO 20025277 D0 NO20025277 D0 NO 20025277D0 NO 20025277 A NO20025277 A NO 20025277A NO 20025277 A NO20025277 A NO 20025277A NO 20025277 D0 NO20025277 D0 NO 20025277D0
- Authority
- NO
- Norway
- Prior art keywords
- peptides
- preparation
- administration form
- pharmaceutical administration
- lhrh antagonist
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical class OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract 2
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 239000002474 gonadorelin antagonist Substances 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical class [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 abstract 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical class OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 abstract 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical class OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 abstract 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical class CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 abstract 1
- 229940022663 acetate Drugs 0.000 abstract 1
- 150000001242 acetic acid derivatives Chemical class 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 238000004220 aggregation Methods 0.000 abstract 1
- 230000002776 aggregation Effects 0.000 abstract 1
- 229940072107 ascorbate Drugs 0.000 abstract 1
- 239000011668 ascorbic acid Chemical class 0.000 abstract 1
- 235000010323 ascorbic acid Nutrition 0.000 abstract 1
- 229940050390 benzoate Drugs 0.000 abstract 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 abstract 1
- 229940001468 citrate Drugs 0.000 abstract 1
- 229940050410 gluconate Drugs 0.000 abstract 1
- 229940097042 glucuronate Drugs 0.000 abstract 1
- 229940001447 lactate Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10024451A DE10024451A1 (de) | 2000-05-18 | 2000-05-18 | Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung |
| PCT/EP2001/005555 WO2001087265A2 (de) | 2000-05-18 | 2001-05-16 | Pharmazeutische darreichungsform für peptide, verfahren zu deren herstellung und verwendung |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20025277L NO20025277L (no) | 2002-11-04 |
| NO20025277D0 true NO20025277D0 (no) | 2002-11-04 |
Family
ID=7642584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20025277A NO20025277D0 (no) | 2000-05-18 | 2002-11-04 | Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelse |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US7718599B2 (cs) |
| EP (1) | EP1282400B1 (cs) |
| JP (2) | JP4944340B2 (cs) |
| KR (1) | KR100580142B1 (cs) |
| CN (1) | CN100342908C (cs) |
| AR (1) | AR028588A1 (cs) |
| AU (1) | AU777185B2 (cs) |
| BG (1) | BG65976B1 (cs) |
| BR (1) | BR0110892A (cs) |
| CA (1) | CA2348167C (cs) |
| CZ (1) | CZ303981B6 (cs) |
| DE (1) | DE10024451A1 (cs) |
| HU (1) | HUP0302050A3 (cs) |
| IL (1) | IL152479A (cs) |
| MX (1) | MXPA02011389A (cs) |
| NO (1) | NO20025277D0 (cs) |
| NZ (1) | NZ522381A (cs) |
| PL (1) | PL203958B1 (cs) |
| RU (1) | RU2253438C2 (cs) |
| SK (1) | SK288118B6 (cs) |
| TW (1) | TWI243059B (cs) |
| UA (1) | UA74578C2 (cs) |
| WO (1) | WO2001087265A2 (cs) |
| ZA (1) | ZA200208761B (cs) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| JP4940492B2 (ja) * | 2000-09-04 | 2012-05-30 | 大正製薬株式会社 | 鉄化合物配合内服液剤 |
| DE10157628A1 (de) * | 2001-11-26 | 2003-06-12 | Zentaris Ag | Injektionslösung eines LHRH-Antagonisten |
| US7214662B2 (en) | 2001-11-27 | 2007-05-08 | Zentaris Gmbh | Injectable solution of an LHRH antagonist |
| RS52966B (sr) * | 2002-09-27 | 2014-02-28 | Zentaris Gmbh | Oblik za terapijsku primenu aktivnih peptida sa produženim oslobađanjem aktivnog sastojka i postupak za njihovo dobijanje |
| DE10332160A1 (de) | 2003-07-15 | 2005-02-03 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
| ES2297688T3 (es) * | 2004-03-12 | 2008-05-01 | Intercell Ag | Procedimiento para solubizar mezclas de peptidos. |
| EP1674082A1 (de) * | 2004-12-22 | 2006-06-28 | Zentaris GmbH | Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel |
| WO2006110118A1 (fr) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Produit cytoprotecteur |
| WO2006110119A1 (fr) * | 2005-04-15 | 2006-10-19 | Victor Pavlovich Kutnyak | Produit antineoplasique (et variantes) |
| CA2817941A1 (en) * | 2010-12-06 | 2012-06-14 | Astron Research Limited | A stable ready-to-use cetrorelix injection |
| CN102144980B (zh) * | 2011-03-07 | 2013-01-09 | 深圳市健元医药科技有限公司 | 一种更加稳定的lhrh拮抗剂冻干粉针剂 |
| WO2015158823A1 (de) * | 2014-04-16 | 2015-10-22 | Veyx-Pharma Gmbh | Veterinärpharmazeutische zusammensetzung und deren verwendung |
| MX391306B (es) * | 2017-01-31 | 2025-03-21 | Veru Inc | COMPOSICIONES PARA LA LIBERACIÓN PROLONGADA DE ANTAGONISTAS DE LA HORMONA LIBERADORA DE GONADOTROPINA (GnRH) |
| BR112021025558A2 (pt) * | 2019-06-17 | 2022-03-03 | Intas Pharmaceuticals Ltd | Formulação estável de cetrorelix e processo para a preparação de uma formulação estável |
| PL3811927T3 (pl) * | 2019-10-24 | 2022-02-07 | Sun Pharmaceutical Industries Ltd | Trwała pozajelitowa postać dawkowania octanu cetroreliksu |
| US20240123021A1 (en) * | 2021-06-25 | 2024-04-18 | Extrovis Ag | Pharmaceutical compositions |
| WO2023017326A1 (en) * | 2021-08-11 | 2023-02-16 | Rk Pharma Inc. | Ready to use compositions of cetrorelix acetate |
| CN115969954A (zh) * | 2023-01-09 | 2023-04-18 | 开封明仁药业有限公司 | 一种注射用西曲瑞克冻干药物组合物及其制备方法 |
| EP4534074A1 (en) * | 2023-10-04 | 2025-04-09 | Ares Trading S.A. | Liquid cetrorelix composition |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE141996C (cs) | ||||
| DD141996A1 (de) * | 1979-02-21 | 1980-06-04 | Ingrid Wolf | Verfahren zur herstellung von lyophilisierten lhrh-praeparationen |
| JPS5892620A (ja) * | 1981-11-28 | 1983-06-02 | Sunstar Inc | インタ−フエロン安定配合組成物 |
| US4565804A (en) | 1984-09-07 | 1986-01-21 | The Salk Institute For Biological Studies | GnRH Antagonists VI |
| US4800191A (en) * | 1987-07-17 | 1989-01-24 | Schally Andrew Victor | LHRH antagonists |
| GB2218102B (en) * | 1988-04-08 | 1992-09-16 | Sandoz Ltd | Calcitonin peptide derivatives |
| JPH0725662B2 (ja) * | 1990-10-22 | 1995-03-22 | アース製薬株式会社 | 使用時調製型上皮細胞成長因子含有水性薬剤の安定化方法 |
| US5643878A (en) * | 1991-09-12 | 1997-07-01 | Ciba-Geigy Corporation | 5-amino-4-hydroxyhexanoic acid derivatives |
| JP3608802B2 (ja) * | 1991-09-20 | 2005-01-12 | 第一サントリーファーマ株式会社 | 安定なカルシトニン医薬組成物及びその製造法 |
| AU4198793A (en) * | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
| EP0666752A4 (en) * | 1992-10-16 | 1996-09-11 | Smithkline Beecham Corp | THERAPEUTIC MICROEMULSIONS. |
| DE4242919A1 (de) * | 1992-12-18 | 1994-06-23 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung von lagerstabilen wässrigen pharmazeutischen Zubereitungen von G-CSF |
| US6828415B2 (en) * | 1993-02-19 | 2004-12-07 | Zentaris Gmbh | Oligopeptide lyophilisate, their preparation and use |
| DE4305225A1 (de) * | 1993-02-19 | 1994-08-25 | Asta Medica Ag | Neues Herstellverfahren für Cetrorelix Lyophilisat |
| JP3636480B2 (ja) * | 1993-05-19 | 2005-04-06 | 科研製薬株式会社 | 凍結乾燥製剤 |
| US6087324A (en) * | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| JP2915296B2 (ja) * | 1993-08-30 | 1999-07-05 | 宇野 潤 | 抗真菌製剤 |
| DE4342091A1 (de) * | 1993-12-09 | 1995-06-14 | Asta Medica Ag | Erzeugnisse zur Anwendung von initial hohen Dosen von Cetrorelix und Herstellung einer Kombinationspackung zur Verwendung bei Therapie von Krankheiten |
| US5595760A (en) | 1994-09-02 | 1997-01-21 | Delab | Sustained release of peptides from pharmaceutical compositions |
| CA2196184C (en) * | 1994-09-09 | 2009-06-09 | Yasutaka Igari | Sustained release preparation containing metal salt of a peptide |
| MY129435A (en) * | 1994-10-26 | 2007-04-30 | Novartis Ag | Pharmaceutical microemulsion preconcentrates |
| EP0726075A1 (en) * | 1995-02-08 | 1996-08-14 | Therapicon Srl | Pharmaceutical non-inorganic saline solutions for endonasal administration |
| DE19542837A1 (de) * | 1995-11-17 | 1997-05-22 | Boehringer Mannheim Gmbh | Polypeptid-enthaltende pharmazeutische Darreichungsformen in Form von Mikropartikeln und Verfahren zu deren Herstellung |
| ATE201983T1 (de) * | 1995-03-10 | 2001-06-15 | Roche Diagnostics Gmbh | Polypeptid-enthaltende pharmazeutische darreichungsformen in form von mikropartikeln und verfahren zu deren herstellung |
| US5942493A (en) * | 1995-11-28 | 1999-08-24 | Asta Medica Aktiengesellschaft | LH-RH antagonists having improved action |
| KR970064620A (ko) * | 1996-03-05 | 1997-10-13 | 임성기 | 사이클로스포린-함유 외용약제 조성물 |
| FR2748205A1 (fr) * | 1996-05-06 | 1997-11-07 | Debio Rech Pharma Sa | Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles |
| IT1282733B1 (it) * | 1996-05-20 | 1998-03-31 | Flarer S A | Composizioni farmaceutiche contenenti ciclosporina ed un veicolante comprendente almeno un estere dell'acido alfa-glicerofosforico |
| US5968895A (en) * | 1996-12-11 | 1999-10-19 | Praecis Pharmaceuticals, Inc. | Pharmaceutical formulations for sustained drug delivery |
| AU5678398A (en) * | 1997-01-29 | 1998-08-18 | Takeda Chemical Industries Ltd. | Sustained-release microspheres, their production and use |
| AU6141498A (en) * | 1997-02-04 | 1998-08-25 | John V. Kosbab | Compositions and methods for prevention and treatment of vascular degenerative diseases |
| DE19712718C2 (de) * | 1997-03-26 | 1999-09-23 | Asta Medica Ag | Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung |
| US20020039594A1 (en) * | 1997-05-13 | 2002-04-04 | Evan C. Unger | Solid porous matrices and methods of making and using the same |
| US6416740B1 (en) * | 1997-05-13 | 2002-07-09 | Bristol-Myers Squibb Medical Imaging, Inc. | Acoustically active drug delivery systems |
| JP2001509487A (ja) * | 1997-07-07 | 2001-07-24 | ペプチケミオ エイジー | ペプチケミオを含有する薬剤学的組成物 |
| ID25908A (id) * | 1998-03-06 | 2000-11-09 | Novartis Ag | Prakonsentrat-prakonsentrat emulsi yang mengandung siklosporin atau makrolida |
| KR100389726B1 (ko) * | 1998-03-06 | 2003-06-27 | 쥬가이 세이야쿠 가부시키가이샤 | 안정한 과립구 콜로니-자극 인자 함유 제제 |
| AU5649299A (en) * | 1998-09-11 | 2000-04-03 | Chugai Seiyaku Kabushiki Kaisha | Protein solution preparation and method for stabilizing the same |
| EP0998940A1 (en) * | 1998-09-30 | 2000-05-10 | Laboratoire Theramex | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
| US6911455B2 (en) * | 1999-12-22 | 2005-06-28 | Smithkline Beecham Corporation | Methods for preparing pharmaceutical formulations |
-
2000
- 2000-05-18 DE DE10024451A patent/DE10024451A1/de not_active Ceased
-
2001
- 2001-05-16 KR KR1020027015424A patent/KR100580142B1/ko not_active Expired - Fee Related
- 2001-05-16 RU RU2002134463/15A patent/RU2253438C2/ru not_active IP Right Cessation
- 2001-05-16 WO PCT/EP2001/005555 patent/WO2001087265A2/de not_active Ceased
- 2001-05-16 PL PL363007A patent/PL203958B1/pl unknown
- 2001-05-16 HU HU0302050A patent/HUP0302050A3/hu unknown
- 2001-05-16 TW TW090111674A patent/TWI243059B/zh not_active IP Right Cessation
- 2001-05-16 IL IL152479A patent/IL152479A/en active IP Right Grant
- 2001-05-16 CZ CZ20023969A patent/CZ303981B6/cs not_active IP Right Cessation
- 2001-05-16 BR BR0110892-1A patent/BR0110892A/pt not_active IP Right Cessation
- 2001-05-16 AU AU74041/01A patent/AU777185B2/en not_active Ceased
- 2001-05-16 EP EP01940482.1A patent/EP1282400B1/de not_active Expired - Lifetime
- 2001-05-16 SK SK1716-2002A patent/SK288118B6/sk not_active IP Right Cessation
- 2001-05-16 NZ NZ522381A patent/NZ522381A/en not_active IP Right Cessation
- 2001-05-16 JP JP2001583734A patent/JP4944340B2/ja not_active Expired - Fee Related
- 2001-05-16 MX MXPA02011389A patent/MXPA02011389A/es active IP Right Grant
- 2001-05-16 CN CNB018177042A patent/CN100342908C/zh not_active Expired - Fee Related
- 2001-05-16 UA UA20021210143A patent/UA74578C2/uk unknown
- 2001-05-18 AR ARP010102371A patent/AR028588A1/es not_active Application Discontinuation
- 2001-05-18 US US09/861,009 patent/US7718599B2/en not_active Expired - Fee Related
- 2001-05-18 CA CA2348167A patent/CA2348167C/en not_active Expired - Fee Related
-
2002
- 2002-10-30 ZA ZA200208761A patent/ZA200208761B/xx unknown
- 2002-11-04 NO NO20025277A patent/NO20025277D0/no not_active Application Discontinuation
- 2002-11-25 BG BG107312A patent/BG65976B1/bg unknown
-
2005
- 2005-01-04 US US11/028,875 patent/US7696149B2/en not_active Expired - Fee Related
-
2011
- 2011-07-04 JP JP2011148199A patent/JP2011213733A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20025277D0 (no) | Farmasöytisk administreringsform for peptider, dens fremstilling samt anvendelse | |
| CO5580776A2 (es) | Formulacion farmaceutica estable en solucion de oxaliplatino | |
| ATE274344T1 (de) | Pharmazeutische zubereitung mit verzögerter wirkstofffreisetzung von phenytoin natrium | |
| RU2002106399A (ru) | Составы моксифлоксацина, содержащие поваренную соль | |
| AR043863A1 (es) | Composiciones que contienen piperacilina y tazobactam, utiles para inyeccioines | |
| BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
| WO2002019969A3 (en) | (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents | |
| ATE203411T1 (de) | Lagerstabile wässrige pharmazeutische zubereitungen von g-csf | |
| NZ524138A (en) | Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents | |
| EP1633327A4 (en) | METHOD FOR IMPROVING THE STABILITY AND DURABILITY OF LIPOSOME COMPLEXES | |
| JP2003506416A5 (cs) | ||
| HRP20010243B1 (hr) | Pripravci koji sadrže difosfonske kiseline | |
| FI3541366T3 (fi) | Exendiinin (9-39) puskuroidut formulaatiot | |
| KR970061270A (ko) | 히토성장호르몬을 함유하는 의약제제 | |
| DE60317039D1 (de) | Peptidborsäuren und deren Verwendung in der Herstellung von Salzen derselben | |
| DE69221252D1 (de) | Lipophile Zusammensetzungen von Oligosaccharid-Antibiotikasalzen | |
| HRP20020298B1 (hr) | Farmaceutske otopine levosimendana | |
| UA40636C2 (uk) | Фармацевтична композиція для одержання стабільного порошку, яка містить як активний компонент асоціацію ацетилсаліцилової кислоти та метоклопраміду, фармацевтичний препарат у формі порошку та спосіб одержання цього препарату | |
| NZ731518A (en) | Formulations of a pi3k/mtor-inhibitor for intravenous administration | |
| DE60027601D1 (de) | Arzneizubereitung mit kontrollierter freisetzung enthaltend tramadol hydrochlorid | |
| JPH0678241B2 (ja) | ｔＰＡ医薬組成物 | |
| JP2005502690A5 (cs) | ||
| ATE390126T1 (de) | Zubereitungen mit verzögerter freigabe enthaltend zink, und herstellung derselben | |
| Schaefer et al. | Randomized phase II study of daily versus continuous-infusion schedules of topotecan in the treatment of extensive-stage small cell lung cancers | |
| IE37288B1 (en) | Pharmaceutical compositions for use in the treatment of certain respiratory diseases or conditions in prematurely born children |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |